Editorial: Digital biomarkers in testing the safety and efficacy of new drugs in mental health: A collaborative effort of patients, clinicians, researchers, and regulators

Johanna Maria Catharina Blom; Cristina Benatti; Deborah Mascalzoni; Fabio Tascedda; Luca Pani

doi:10.3389/fpsyt.2022.1107037

Editorial: Digital biomarkers in testing the safety and efficacy of new drugs in mental health: A collaborative effort of patients, clinicians, researchers, and regulators

Front Psychiatry. 2023 Jan 11:13:1107037. doi: 10.3389/fpsyt.2022.1107037. eCollection 2022.

Authors

Johanna Maria Catharina Blom¹, Cristina Benatti¹, Deborah Mascalzoni^{2

3}, Fabio Tascedda⁴, Luca Pani^{1

5

6}

Affiliations

¹ Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy.
² Department of Public Health and Caring Sciences, Centre for Research Ethics and Bioethics, Uppsala University, Uppsala, Sweden.
³ Institute for Biomedicine, EURAC Research, Bolzano, Italy.
⁴ Department of Life Science, University of Modena and Reggio Emilia, Modena, Italy.
⁵ Department of Psychiatry and Behavioral Sciences, University of Miami School of Medicine, Miami, FL, United States.
⁶ Relmada Therapeutics, Coral Gables, FL, United States.

No abstract available

Keywords: cognition; data protection and privacy; digital biomarkers; digital endpoints; digital phenotyping; mobile sensing; psychiatry; remote assessment.

Publication types

Editorial